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Abstract
Background: Parkinson’s disease (PD) and cerebral ischemia are chronic and acute neurodegenerative diseases,
respectively, and onsets of these diseases are thought to be induced at least by oxidative stress. PD is caused by
decreased dopamine levels in the substantia nigra and striatum, and cerebral ischemia occurs as a result of local
reduction or arrest of blood supply. Although a precursor of dopamine and inhibitors of dopamine degradation
have been used for PD therapy and an anti-oxidant have been used for cerebral ischemia therapy, cell death
progresses during treatment. Reagents that prevent oxidative stress-induced cell death are therefore necessary for
fundamental therapies for PD and cerebral ischemia. DJ-1, a causative gene product of a familial form of PD,
PARK7, plays roles in transcriptional regulation and anti-oxidative stress, and loss of its function is thought to result
in the onset of PD. Superfluous oxidation of cysteine at amino acid 106 (C106) of DJ-1 renders DJ-1 inactive, and
such oxidized DJ-1 has been observed in patients with the sporadic form of PD.
Results: In this study, a compound, comp-23, that binds to DJ-1 was isolated by virtual screening. Comp-23
prevented oxidative stress-induced death of SH-SY5Y cells and primary neuronal cells of the ventral
mesencephalon but not that of DJ-1-knockdown SH-SY5Y cells, indicating that the effect of the compound is
specific to DJ-1. Comp-23 inhibited the production of reactive oxygen species (ROS) induced by oxidative stress
and prevented excess oxidation of DJ-1. Furthermore, comp-23 prevented dopaminergic cell death in the
substantia nigra and restored movement abnormality in 6-hydroxyldopamine-injected and rotenone-treated PD
model rats and mice. Comp-23 also reduced infarct size of cerebral ischemia in rats that had been induced by
middle cerebral artery occlusion. Protective activity of comp-23 seemed to be stronger than that of previously
identified compound B.
Conclusions: The results indicate that comp-23 exerts a neuroprotective effect by reducing ROS-mediated
neuronal injury, suggesting that comp-23 becomes a lead compound for PD and ischemic neurodegeneration
therapies.
Background
Parkinson’s disease (PD) is a chronic neurodegenerative
disease caused by dopaminergic cell death, and genetic
and environmental factors are thought to affect the
onset of PD. Cerebral infarction and stroke are acute
neurodegenerative diseases caused by ischemic injury.
Onsets of these diseases are thought be induced at least
by oxidative stress, but the precise mechanisms are still
not known. Although a precursor of dopamine, inhibi-
tors of dopamine degradation and dopamine releasers
have been used for PD therapy and an anti-oxidant have
been used for cerebral infarction and stroke, cell death
progresses during treatment. Identification of com-
pounds or proteins that inhibit oxidative stress-induced
neuronal cell death is necessary.
DJ-1 was first identified by our group as a novel onco-
gene product [1] and later found to be a causative gene
product of a familial form of PD, PARK7 [2]. DJ-1 plays
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tive stress reaction [10-13], and loss of its function is
thought to result in the onset of PD. DJ-1 has three
cysteines at amino acid numbers 46, 53, and 106 (C46,
C53, and C106, respectively). Although oxidation of
C106 is necessary for DJ-1 to exert its activity [12-15],
further oxidation of C106 is thought to render DJ-1
inactive [16,17], and such oxidized DJ-1 has been
observed in patients with the sporadic form of PD and
Alzheimer disease [18,19].
We have shown that administration of DJ-1 protein
dramatically reduced dopaminergic cell death and
restored locomotion defect in PD model rats into which
6-hydroxydopamine (6-OHDA) had been injected [20]
and that intrastriatal injection of DJ-1 markedly reduced
infarct size in cerebral ischemia in rats [21], suggesting
that DJ-1 is a pharmaceutical target for PD and cerebral
ischemia. Another group also reported protective activ-
ity of DJ-1 against stroke [22]. Furthermore, we identi-
fied compounds that bind to the C106 region of DJ-1,
and these compounds including compounds A and B,
like DJ-1 protein, prevented oxidative stress-induced
dopaminergic cell death and restored locomotion defect
in PD model rats and also reduced infarct size in cere-
bral ischemia in rats [23-25]. These compounds were
found by screening the University Compound library,
which contains approximately 30,000 compounds.
In this study, we further screened DJ-1-binding com-
pounds from the Zinc compound library that contains
approximately 2,500,000 compounds. Of the compounds
identified, compound-23 (comp-23) protected oxidative
stress-induced cell death bothi nc u l t u r e dc e l l sa n di n
PD and ischemia model rats and mice, and the protec-
tive activity of comp-23 seemed to be stronger than that
of compound B.
Results
Isolation of a DJ-1-binding compound
We have previously reported the isolation of DJ-1-bind-
ing compounds in silico using a Fujitsu Bioserver from a
compound library, which is organized by the University
Compound Project at the Foundation for Education of
Science and Technology and contains approximately
30,000 compounds [23]. Based on the X-ray crystal
structures of DJ-1 [26,27], compounds binding to the
C106 region of DJ-1 were identified. In this study, we
screened DJ-1-binding compounds in silico from the
Zinc compound library that contains approximately
2,500,000 compounds using the same method as that
described previously [23]. Twenty-five compounds
whose docking score toward DJ-1 was less than -100
Kcal/mole were obtained. The effects of candidate com-
pounds on oxidative stress-induced cell death were
examined. Human dopaminergic neuroblastoma cell line
SH-SY5Y cells were incubated with 1 μM of each com-
pound for 20 hours and then treated with 400 μM
H2O2 for 3 hours, and cell viability was measured by
an MTT assay (Figure 1A). Results of some com-
pounds were shown. Cell death induced by addition of
H2O2 was significantly inhibited only by addition of
compound-23 (comp-23) under this condition, and the
other compounds, including compound B (comp-B)
that was reported previously [23], had a little effect
against cell death induced by less than 400 μMH 2O2.
Therefore, we concentrated on analyses of comp-23 in
further study. Structures of comp-23 and comp-B are
s h o w ni nF i g u r e1 B .
Binding of comp-23 to DJ-1 was confirmed by using a
quartz crystal microbalance in which compound-23,
compound D (Figure 1B) or bovine serum albumin
(BSA) was fixed on a sensor chip and recombinant DJ-1
was applied. Compound D is a negative control com-
pound whose docking score toward DJ-1 was more than
+200 Kcal/mole. As shown in Figure 1C, comp-23
b o u n dt oD J - 1 ,a n dc o m p o u n dDa n dB S Ah a r d l y
bound to DJ-1. The binding constant (Kd) of comp-23
to DJ-1 is calculated to be 1.03 × 10
-7 M.
Effects of DJ-1-binding compound-23 on oxidative stress-
induced cell death and ROS production
The effect of comp-23 on oxidative stress-induced cell
death was examined. SH-SY5Y cells were incubated
with 1 μM comp-23 for 20 hours and then treated with
250 μMH 2O2 for 24 hours or 450 μMH 2O2 for 3
hours or with 50 μM 6-OHDA for 24 hours or 125 μM
6-OHDA for 1 hour, and cell viability was measured by
an MTT assay (Figures 2A-D). Without the compound,
90-70% of the cells died and vehicle (DMSO) control of
cells had little effect on protection against cell death.
With comp-23, on the other hand, cell death induced by
addition of H2O2 or 6-OHDA was significantly inhib-
ited. Compound D had little effect. It should be noted
that comp-23 at doses used in this study had no toxicity
against culture cells.
The effect of comp-23 on production of reactive oxy-
gen species (ROS) was then examined. SH-SY5Y cells
were pretreated with 1 μM comp-23 for 20 hours and
then treated with DCFA-DA and exposed to 40 μM
6-OHDA for 10 min. ROS were then measured by using
a fluorescence spectrophotometer. As shown in
Figure 2E, comp-23, but not comp-D, significantly
reduced the level of ROS in cells that had been treated
with 6-OHDA compared to that in vehicle-control cells.
Primary neuronal cells of the ventral mesencephalon
were prepared from rat embryos on the 17-19th days of
gestation. To examine the presence of dopaminergic
neurons in cell culture, cells were immunostained using
anti-NeuN and anti-TH antibodies to identify all of the
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Figure 1 Identification of DJ-1-binding compounds and effects of DJ-1-binding compounds on oxidative stress-induced cell death.
(A) SH-SY5Y cells were pretreated with 1 μM of each compound for 20 hours and then treated with H2O2 for 3 hours, and cell viability was
measured by an MTT assay. ‘’-’’ indicates cells not treated with compounds. Significance: ** P < 0.01 versus vehicle (DMSO) control without
compounds. (B) Chemical structures of compound-23, -B and -D. (C) Binding of compounds to DJ-1 was examined by using a quartz crystal
microbalance as described in Methods. Hz indicates decreased frequency of a sensor chip.
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Figure 2 Effects of DJ-1-binding compound-23 on oxidative stress-induced cell death. (A-D) SH-SY5Y cells were pretreated with 1 μMo f
comp-23 for 20 hours and then treated with 250 μMH 2O2 for 24 hours (A) and 450 μMH 2O2 for 3 hours or with 50 μM 6-OHDA for 24 hours
(C) and 125 μM 6-OHDA for 1 hour, and cell viability was measured by an MTT assay. “-’’ indicates cells not treated with comp-23. Significance:
** P < 0.01 versus vehicle (DMSO) control without compound. (E) SH-SY5Y cells were pretreated with 1 μM of comp-23 for 20 hours, treated
with 5 μM DCFH-DA for 10 min at 37°C, and then treated with 40 μM 6-OHDA for 10 min. The amounts of ROS in cells were measured using a
fluorescence spectrophotometer.
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Page 4 of 19neurons and dopaminergic neurons, respectively, and
cell nuclei were stained with DAPI. Primary neuronal
cells were pretreated with 1 μM comp-23 for 20 hours
and then treated with 200 μMH 2O2 for 3 hours. The
results showed that comp-23, but not comp-D, signifi-
cantly reduced cell death (Figure 3B).
DJ-1-specific reaction of compound-23
To know the specificity of comp-23 to DJ-1, the effect
of comp-23 on oxidative stress-induced cell death was
examined using DJ-1-knockdown SHSY5Y cells (KD-
SH-SY5Y cells) that had been established previously
[15]. The expression levels of DJ-1 in KD-SH-SY5Y cells
and parental SH-SY5Y cells (host) were examined by
Western blotting with an anti-DJ-1 antibody and quanti-
fied by normalization of the level of DJ-1 compared to
that of b-actin (Figure 4A). The results showed that
about 60% of DJ-1 expression was knocked down in
KD-SH-SY5Y cells. When SH-SY5Y and KD-SH-SY5Y
cells were treated with 100 μMH 2O2 for 3 hours, about
25% and 98% of the cells, respectively, died (Figures 3B
a n d3 C ) ,c o n f i r m i n gt h a tD J - 1 - k n o c k d o w nc e l l sa r e
more susceptible to oxidative stress than are parental
cells as described previously [10,12,13,15]. Pretreatment
of cells with com-23 for 20 hours before the addition of
various concentrations of H2O2 significantly abrogated
cell death of parental SH-SY5Y cells but not that of KD-
SH-SY5Y cells (Figures 3B and 3C). These results clearly
indicate that DJ-1-binding compound-23 functions in a
DJ-1-dependent manner and that there is a threshold
amount of DJ-1 for DJ-1-binding compounds to func-
tion in cells.
Lack of scavenging activity for hydroxyl radical (
.OH)
Recent studies suggest that H2O2 is produced by mito-
chondrial dysfunction or autoxidation of dopamine and
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Figure 3 Effects of compound-23 on oxidative stress-induced death of rat mesencephalic neurons. (A) Rat mesencephalic cultured
neurons were fixed and immunostained by anti-NeuN and anti-TH antibodies. Cells were then stained with DAPI. The cells were then reacted
with a rhodamine-conjugated anti-rabbit IgG or fluorescein isothiocyanate-conjugated anti-mouse IgG and observed under an All-in-on
microscope. (B) Rat mesencephalic cultured neurons were treated with 1 μM of comp-23 for 20 hours and with 200 μMH 2O2 for 3 hours, and
cell viability was measured by an MTT assay. Significance: **P < 0.01 versus vehicle (DMSO) control without compound.
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Page 5 of 196-OHDA, and then
.OH is easily generated in the pre-
sence of Fe
2+ [28,29]. It is known that
.OH is one of
most potent neurotoxic factors in dopaminergic neuro-
degeneration. To clarify whether comp-23 can directly
scavenge
.OH, we further performed electron spin reso-
nance (ESR) analysis using a spin trapper, 5,5-dimethyl-
1-pyrroline-N-oxide (DMPO). As an internal reference,
Mn
2+ signal was detected as two small peaks at both
edges (Figure 5A, Control). Although no marked signal
was detected in the absence of Fe
2+, four major peaks
with an intensity ratio of 1:2:2:1 appeared at the mid-
section between the Mn
2+ signal in the presence of
H2O2 and Fe
2+ (Figure 5A, H2O2). This characteristic
quartet signal was almost completely suppressed by
thiourea (Figure 5A, H2O2 + thiourea), a specific
.OH
scavenger, suggesting that the quartet signal indicates
DMPO-OH spin adduct. In contrast, H2O2-induced
DMPO-OH signal could not be reduced by comp-23
even at a high concentration of 100 μM( F i g u r e5 A ) .
These results indicate that comp-23 is not a simple
anti-oxidant.
Effects of compound-23 on oxidation and dimer
formation of DJ-1
We have reported that comp-B prevented excess oxida-
tion of DJ-1 in cells that had been treated with H2O2 or
6-OHDA [23]. To examine whether this is true for
comp-23, SH-SY5Y cells were first incubated with
comp-23 or comp-B for 20 hours and treated with var-
ious amounts of H2O2. Oxidation of DJ-1 was analyzed
by isoelectric focusing. As shown in Figure 6A, reduced
and oxidized forms of DJ-1 were observed in cells in the
absence of H2O2. After cells were treated with H2O2,
the level of oxidized DJ-1 increased in cells that had not
been treated with compound. No or little increase of the
oxidized DJ-1 level was, on the other hand, observed in
cells that had been incubated with comp-23 or with
comp-B, indicating that comp-23, like comp-B, prevents
excess oxidation of DJ-1.
Since DJ-1 works as dimer, the effect of comp-23 on
dimer formation of DJ-1 was examined. SY-SY5Y cells
were incubated with 1 μMc o m p - 2 3o rw i t h1μM
comp-B for 20 hours, treated with various amounts of
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Page 6 of 19Figure 5 ESR analysis. (A) Typical ESR spectra of DMPO-OH spin adducts in the control (without H2O2), 100 μMH 2O2 (with 25 μMF e
2+), H2O2
(with Fe
2+) + 500 mM thiourea, and H2O2 (with Fe
2+) + comp-23 at 1, 10 and 100 μM. (B) Semi-quantitative measurement of in vitro
.OH
generation. Each value is the mean ± SEM of eight determinations, based on H2O2/Fe
2+ as 100%.
Kitamura et al. Molecular Neurodegeneration 2011, 6:48
http://www.molecularneurodegeneration.com/content/6/1/48
Page 7 of 19H2O2 for 3 hours and then treated with disuccinimidyl
suberate (DSS) or with dimethyl sulfoxide (DMSO) as a
vehicle control. Proteins extracted from cells were ana-
lyzed by Western blotting with an anti-DJ-1 antibody
(Figure 6B). The results showed that the levels of dim-
mer DJ-1 observed in DSS-treated cells were not chan-
ged in the presence or absence of DJ-1-binding
compounds, indicating that both comp-23 and comp-B
do not affect dimer formation of DJ-1.
Effects of compound-23 on oxidative stress-induced cell
death and movement defect in Parkinson’s disease
model rats
To examine the effect of DJ-1-binding comp-23 on PD
phenotypes in vivo,w eu s e dP Dm o d e lr a t si nw h i c h
6-OHDA was stereotaxically microinjected into the unilat-
eral (left) mesencephalon. Administration of methamphe-
tamine to animals induced movement ipsilateral to the
injection site, and the rotational behavior was significantly
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Page 8 of 19reduced by coadministration of comp-23 at 7 days after
injection (Figure 7). The total number of rotations of rats
(Figure 7A) and number of rotations during the course of
administration of methamphetamine (Figure 7B) were sig-
nificantly reduced. As shown in Figure 8A, TH-immuno-
positive neurons were obviously preserved in the
ipsilateral substantia nigra pars compacta (SNpc) of comp-
23-treated animals compared to those in animals injected
with 6-OHDA alone at 10 days post-lesion. Semi-quantita-
tive analysis of nigral TH-immunopositive neurons
showed that while microinjection of 6-OHDA alone
caused a significant loss of dopaminergic neurons (5 ± 2%
survival rate), loss of dopaminergic neurons was signifi-
cantly inhibited by simultaneous administration of comp-
23 (60 ± 13%) (Figure 8B). Comp-23 alone did not affect
TH-immunoreactivity in the Snpc that had not been
injected with 6-OHDA (Figure 8). In the ipsilateral stria-
tum, although TH immunoreactivity almost completely
disappeared in rats injected with 6-OHDA alone, TH
immunoreactivity was restored by coadministration of
comp-23 (Figure 9A). The intensity of TH-immunoreac-
tivity in the striatal quadrants, including the dorsal, medial,
lateral and ventral parts (Figure 9B), was significantly
increased in comp-23-treated animals compared to the
intensity in 6-OHDA-treated animals (Figure 9C).
Effect of compound-23 on infarct size in focal cerebral
ischemia and reperfusion in rats in a dose-dependent
manner
Comp-23 was microinjected intrastriatally into the left
striatum of rats, and left middle cerebral artery
occlusion (MCAO) for 90 min and reperfusion were
performed at 30 min after microinjection of comp-23.
As shown in Figure 10A, although a marked regional
loss of 2,3,5-triphenyltetrazolium chloride (TTC)-stain-
ing occurred in the ipsilateral cerebral cortex and stria-
tum in vehicle-injected rats at 24 hours after MCAO,
the area of TTC staining lost was smaller with microin-
jection of comp-23. In quantitative analysis, each infarct
area was smaller and the total infarct volume was signif-
icantly reduced by the administration of comp-23 com-
pared with that in vehicle-injected rats (Figures 10B and
10C). Thus, comp-23 exhibits neuroprotective effects by
direct microinjection into the striatum of brain ischemic
rats (Figure 10). Therefore, we further examined
whether or not peripheral administration of comp-23
induces neuroprotection. Before and after 120-min
MCAO, rats were intraperitoneally administered comp-
23. Subsequently, we assessed the neuroprotective effect.
As shown in Figure 11, focal ischemia-induced neurode-
generation was also prevented by peripheral administra-
tion of comp-23 in a dose-dependent manner. These
results indicate that comp-23 has neuroprotective activ-
ity against oxidative stress-induced stroke and Parkin-
son’s disease model rats.
Effect of peripheral administration of compound-23 on
rotenone-induced movement dysfunction in mice
Although 6-OHDA-microinhected rat PD model is use-
ful in pharmacological screening of drugs, the blood-
brain barrier (BBB) is broken by the direct microinjec-
tion into the substantia nigra (ventral mesencephalon).
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tion to C57BL/6 mice with rotenone (a selective inhibi-
tor for mitochondrial complex I) at 30 mg/kg for 28-56
days selectively induced nigrostriatal dopaminergic neu-
rodegeneration and motor deficits, and increased the
cytoplasmic accumulation of a-synuclein in surviving
dopaminergic neurons, similar to the early stage of PD
neuropathological episodes [30,31]. To investigate
whether peripheral administration of comp-23 protects
motor function from damage caused by the chronic oral
administration of rotenone (30 mg/kg p.o. once a day
for 56 days), we treated C57BL/6 mice with comp-23 (1
mg/kg i.p. once a day for 56 days) 30 min before the
oral administration of rotenone. To identify deficits in
motor coordination, rotenone-treated mice were tested
weekly on the accelerating rota-rod. Under this condi-
tion, vehicle-treated control mice usually remained on
the rota-rod for over 200 sec under stepwise accelera-
tion. Rotenone-treated mice showed marked reduction
in endurance time and in the percentage of mice
remaining on the rota-rod (running survivors). In con-
trast, comp-23 (1 mg/kg i.p.)p r o v i d e das i g n i f i c a n t
functional recovery of the retention time on the rota-
rod (Figure 12). Thus, chronic peripheral administration
of comp-23 improves rotenone-induced Parkinsonian
motor dysfunction.
Discussion
In this study, we identified a new DJ-1-binding com-
pound, compound-23 (comp-23), from the Zinc com-
pound library, and we found that comp-23 prevented
oxidative stress-induced cell death both in cultured cells
and in PD and ischemia model rats and mice. Comp-23
prevented cell death even at a high concentration of
H2O2, a condition in which DJ-1-binding compound B
did not show protective activity against cell death, sug-
gesting that activity of comp-23 is stronger than that of
compound B at least in cultured cells. Structures of
comp-23 and comp-B appear similar at a glance but are
clearly different, especially in the position of an amino
group and benzene ring. Since the X-ray co-crystal
structure of DJ-1 with compound B has not yet been
elucidated, an exact binding structure of compound B
within DJ-1 is not known at present. Determination of
the structure-activity relationships between DJ-1 and
DJ-1-binding compounds will be necessary to establish
DJ-1-binding compounds that are more effective than
compounds B and 23. The Zinc compound library used
in this study is freely available. If other libraries are used
for screening of DJ-1-binding compounds, novel com-
pounds might be obtained.
Although comp-23 lacks direct scavenging activity
against
.OH (Figure 5), comp-23 protected SH-SY5Y
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induced cell death (Figures 1, 2, and 3). Since comp-23
did not show a protective effect against oxidative stress-
induced cell death in DJ-1-knockdown SH-SY5Y cells
(Figure 4), comp-23 works in a DJ-1-dependent manner.
Since a residual amount of DJ-1 was still expressed in
DJ-1-knockdown SH-SY5Y cells, no protective activity
of comp-23 in DJ-1-knockdown cells suggests that there
is a threshold amount of DJ-1 for DJ-1-binding com-
pounds to function in cells. Comp-23 prevented dopa-
minergic cell death both in the substantia nigra and
striatum in 6-OHDA-administered PD model rats,
resulting in suppression of locomotion defect of rats
(Figures 7, 8, 9, 10, 11). Since a precursor of dopamine,
inhibitors of dopamine degradation and dopamine relea-
sers are used for PD therapy at present and since these
drugs are used for symptomatic therapy, cell death pro-
gresses during treatment. In the present study, the intra-
peritoneal injection of comp-23 at before and after MCAO
induced neuroprotection in a dose-dependent manner
(Figure 11), and peripheral administration of comp-23 for
56 days prevented rotenone-induced Parkinsonian motor
deficit (Figure 12). Based on these observations, we con-
sider that comp-23 binds to endogenous DJ-1 protein
after passing through the BBB and that this DJ-1-comp-23
complex shows the neuroprotective effect against ROS-
mediated dopaminergic neurodegeneration. Thus, there is
a possibility that chronic peripheral administration of
comp-23 delays the progression of motor dysfunction in
PD and/or brain stroke.
Comp-23 is not a simple anti-oxidant (Figure 5) and
prevented excess oxidation of DJ-1 in cells that had
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Page 11 of 19been treated with various amounts of H2O2 (Figure 6A).
Since excess oxidation of DJ-1 renders DJ-1 inactive, it
is thought that comp-23 activates DJ-1 or maintains
active forms of DJ-1, thereby affecting downstream tar-
gets of DJ-1. DJ-1, for instance, activates Nrf2, a master
transcription factor of redox-related genes, by sequester-
ing Keap1, a negative factor of Nrf2 [32], and also acti-
vates the PI3 kinase/AKT pathway by inhibiting PTEN,
a negative effecter of the PI3 kinase/AKT pathway,
through direct binding with PTEN [22,33,34]. Screening
strategy is to identify compounds that bind to weakly
oxidized DJ-1 with an SO2Hf o r mo fC 1 0 6u s i n ga
model of such an oxidized DJ-1. Since reduced DJ-1 and
oxidized DJ-1 are unable to be separately purified due
to technical problem at present, we are not able to
determine which form of DJ-1 is bound by comp-23. In
vitro binding assays showed that comp-23 bound to
recombinant DJ-1 that contains equal molar ratio of
reduced and oxidized DJ-1 (Figure 1C), suggesting that
comp-23 binds to both reduced DJ-1 and oxidized DJ-1.
Furthermore, we examined dimer formation of DJ-1 in
t h ep r e s e n c ea n da b s e n to fc o m p - 2 3 .T h er e s u l t s
showed that comp-23 did not affect dimer formation of
DJ-1 (Figure 6B). Since DJ-1 works as dimer, it is
t h o u g h tt h a td i m e rD J - 1c o m p l e x e dw i t hc o m p - 2 3
shows protective activity against oxidative stress-induced
neurodegeneration.
Reactive oxygen species are massively produced in the
brain after cerebral ischemia and reperfusion. The anti-
oxidant edaravone (3-methyl-1-phenyl-2-pyrazolin-5-
Figure 10 Intrastriatal injection of DJ-1-binding compound-23 (comp-23) reduces infarct size after focal cerebral ischemia and
reperfusion. (A) Representative photographs showing coronal brain sections at +3, +1, -1, -3, -5, and -7 mm anterior-posterior from the bregma
with TTC staining at 1 day after MCAO in sham-operated rats (n = 5) and MCAO-ischemic rats injected with sterilized physiological saline in the
presence of the vehicle (4 μL, 1% DMSO, n = 5) or comp-23 (4 nmol/4 μL containing 1% DMSO, n = 4), at 30 min before MCAO (90 min). Scale
bar: 1 mm (Sham in A). (B and C) Quantitative analysis of infarct area (B) and volume (C). Data are means ± SEM. Significance (Student’s t-test in
B; Bonferroni/Dunn post hoc comparisons after ANOVA in C): *P < 0.05, ***P < 0.001 versus sham-operated rats. †P < 0.05, †††P < 0.001 versus
vehicle-injected rats.
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apy and is effective within 24 hours after onset of stroke.
It has been reported that DJ-1 immunoreactivity in
human brain astrocytes is dependent on infarct presence
and infarct age [35], that DJ-1 is expressed in motor
neurons after transient spinal cord ischemia in rabbits
[36] and that loss of DJ-1 increases the sensitivity to
excitotoxicity and ischemia [27]. We and other group
have reported that injection of DJ-1 or infection of DJ-
1-containing virus reduced infarct size in cerebral ische-
mia in rats [21,22]. Furthermore, we have shown that
administration of DJ-1-binding compound B also
reduced infarct size of cerebral ischemia in rats [24]. It
is therefore thought that, like a PD model, comp-23
maintains activated forms of DJ-1 to activate Nrf2 and
the AKT pathway, leading to reduction of ROS and to
promotion of cell growth in ischemia model rats.
Conclusions
In this study, we identified a new DJ-1-binding com-
pound, comp-23. Comp-23 prevented dopaminergic cell
death in the substantia nigra and restored movement
abnormality in 6-hydroxyldopamine-injected PD model
rats and in rotenone-treated PD model mice. Comp-23
also reduced infarct size of cerebral ischemia in rats that
had been induced by middle cerebral artery occlusion.
Protective activity of comp-23 seemed to be stronger
than that that of previously identified compound B at
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Figure 11 Intraperitoneal administration of DJ-1-binding compound-23 (comp-23) reduces infarct size after focal cerebral ischemia
and reperfusion. (A) Representative photographs showing coronal brain sections at +3, +1, -1, -3, -5, and -7 mm anterior-posterior from the
bregma with TTC staining at 1 day after MCAO in sham-operated rats (n = 6) and MCAO-ischemic rats intraperitoneally administered sterilized
physiological saline in the presence of the vehicle (1% DMSO, n = 8) or comp-23 (0.1, 1 and 10 mg/kg containing 1% DMSO, n = 5 in each
group), before 10 min and after 2 h of the reperfusion from 120-min MCAO. Scale bar: 1 mm (Sham in A). (B and C) Quantitative analysis of
infarct area (B) and volume (C). Data are means ± SEM. Significance (Student’s t-test in B; Bonferroni/Dunn post hoc comparisons after ANOVA in
C): ***P < 0.001 versus sham-operated rats. †P < 0.05, †††P < 0.001 versus vehicle-injected rats.
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pound for PD and stroke.
Methods
Materials
N-[4-(8-methyl(4-hydroimidazo[1,2-a]pyridin-2-yl))phe-
nyl](3,4,5-trimethoxyphenyl)carboxamide, which is DJ-1-
binding compound-23 (comp-23), was synthesized and
obtained by Enamine Ltd. (Kiev, Ukraine). 6-Hydroxydo-
pamine (6-OHDA) and DCFH-DA were purchased from
Sigma (St. Louis, MO, USA) and from Invitrogen (Carls-
bad, CA, USA), respectively. Mouse anti-tyrosine
hydroxylase (TH), chicken anti-TH and anti-NeuN anti-
bodies were purchased from Sigma, Chemicon (Teme-
cula, CA, USA) and Chemicon, respectively. The ABC
Elite kit from Vector Laboratories (Burlingame, CA,
USA) was used. Methamphetamine was obtained from
Dainippon Sumitomo Pharmaceutical Co., Ltd. (Osaka,
Japan).
Cell culture
Human SH-SY5Y and its DJ-1-knockdown cells were cul-
tured in Dulbecco’s modified Eagle’sm e d i u m( D M E M )
Figure 12 Suppression of rotenone-induced behavioral dysfunction by DJ-1-binding compound-23. Rotenone (suspended in 0.5% CMC)
was orally administered to C57BL/6 mice at a dose of 30 mg/kg per day for 56 days. In addition, we injected mice with vehicle (closed circles;
1% DMSO, n = 22) or comp-23 (open squares; 1 mg/kg i.p., n = 16) once a day for 56 days, 30 min before the oral administration of rotenone.
The vehicle control mice (open circles; n = 8) were received 0.5% CMC (p.o.) and 1% DMSO (i.p.) for 56 days. (A) The rota-rod test was
performed every week. The speed of the rotating rod was accelerated in a stepwise manner (2 r.p.m, steps at intervals of 30 sec). Mice that had
received oral rotenone showed significant motor dysfunction. This rotenone-induced dysfunction was significantly restored by administration of
comp-23. Significance: *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle. †p < 0.05, ††p < 0.01, †††p < 0.001 vs rotenone alone. (B and C) Time-
dependent changes in the percentage (%) of mice remaining on the rotating rod at 0 (B) and 56 days (C). Mice that had received oral rotenone
showed significantly greater motor dysfunction than those that had received vehicle at 56 days (p = 0.0016 by the log-rank test, C). Rotenone-
induced motor dysfunction was significantly restored by administration of comp-23 (p = 0.0019 by the log-rank test, C).
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SH-SY5Y cells was described previously [17].
Screening of DJ-1-binding compounds
Information on the X-ray crystal structures of reduced
D J - 1a n do x i d i z e dD J - 1a tC 1 0 6a sa nS O 2Hf o r mw a s
obtained from a web site (http://www.rcsb.org/pdb/). To
obtain the structure of DJ-1 containing H2O, the X-ray
crystal structure of DJ-1 was modified using BioMed-
CAChe software (Fijitsu, Tokyo, Japan). Compounds
were screened by targeting C106 of this structure on
FastDock software (Fijitsu) in BioServer hardware
(Fujitsu) according to the manufacturer’sp r o t o c o l .
Briefly, the BioServer hardware used is PC clusters with
40 core of CPU of Xeon5355 (Fujitsu), OS of Red Hat
3.4.5-2 (Linux version 2.6.9-34) and 1.0 TB Hard Disk.
The other conditions were exactly the same as those
described previously [23].
Cell viability assay
Cells were cultured in a 96-well plate and treated with
various amounts of hydrogen peroxide or 6-OHDA. Cell
viability was then measured by a 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
using a cell counting kit -8 (DOJINDO, Osaka, Japan).
Binding of compound-23 to DJ-1 by a quartz crystal
microbalance
Fixation of compounds on a sensor chip of QCM (Affi-
nix Q, Initium, Tokyo, Japan) was carried out as follows.
The sensor chip was washed with a solution containing
H2O2 and sulfonic acid (molar ratio = 1:3), and then it
was incubated with 4 μLo f1μM compound dissolved
in chloroform until the solution had evaporated. To the
sensor chips fixed with compounds in Affinix Q, 8 μL
of 1 μg/μL DJ-1 was applied, and their frequency was
measured according to the manufacturer’s protocol.
Primary neuronal culture of the ventral mesencephalon
Cultures of the rat mesencephalon were established
according to methods described previously [37]. The
ventral two-thirds region of the mesencephalon was dis-
sected from rat embryos on the 17-19th days of gesta-
tion. The dissected regions included dopaminergic
neurons from the substantia nigra and the ventral teg-
mental area but not noradrenergic neurons from the
locus ceruleus. Neurons were dissociated mechanically
and plated out onto 0.1% polyethyleneimine-coated 24-
well plates at a density of 2.5 × 10
6 cells/well. The cul-
ture medium consisted of DMEM containing 10% fetal
calf serum for 2 days and DMEM containing 2% B-27
supplement (Invitrogen) and 2 μg/mL aphidicolin
(Sigma) without fetal calf serum from the third day
onwards. The animals were treated in accordance with
guidelines published in the NIH Guide for the Care and
Use of Laboratory Animals. After fixation, cultured cells
were incubated with chicken anti-TH (diluted at 1:200)
and anti-NeuN (1:200) antibodies for 24 hours at 25°C.
The cells were also stained with 4’,6-diamidino-2-pheny-
lindole (DAPI). The cells were then reacted with a rho-
damine-conjugated anti-rabbit IgG or fluorescein
isothiocyanate-conjugated anti-mouse IgG and observed
under an All-in-on microscope (Biorevo BZ-9000,
Keyence).
To examine the effects of DJ-1-binding compounds on
oxidative stress-induced cell death, the cells were cul-
tured in the presence or absence of 1 μM of each com-
pounds for 20 hours and then treated with 200 μM
H2O2 for 3 hours. Cell viabilities were then examined by
an MTT assay.
Detection of production of ROS
8×1 0
5 SH-SY5Y cells in a 96-well plate were pretreated
with 1 μM of comp-23 for 20 hours and then treated
with 40 μM 6-OHDA for 10 min after the addition of
10 μM DCFA-DA (Invitrogen) for 15 min. The amounts
of ROS in cells were measured using a fluorescence
spectrophotometer at extension of 485 nm and emission
of 530 nm.
Isoelectric focusing
SH-SY5Y cells were incubated with 1 μM compound-23
or compound-B for 24 hours and then treated with var-
ious amounts of H2O2 for 10 min. Proteins extracted
from the cells were separated in the pH 5-8 range of
isoelectric focusing phoresis gel, transferred to nitrocel-
lulose membranes, and blotted with an anti-DJ-1 poly-
clonal antibody as described previously [10].
Dimer formation
SH-SY5Y cells in 6-well plates were incubated with 1
μM compound-23 or compound-B for 20 hours and
then treated with various amounts of H2O2 for 3 hours.
Cells were then treated with 0.5 mM DSS or DMSO for
30 min, and proteins extracted from cells were analyzed
by Western blotting with an anti-DJ-1 antibody.
ESR spectrometry
The hydroxyl radical (
.OH) was monitored by ESR spec-
trometry with 5,5-dimethyl-1-pyrroline-N-oxide (DMPO;
Labotec Ltd., Tokyo, Japan), a spin trapper. In a final
volume of 200 μL of 100 mM phosphate buffer (PB),
comp-23 (1-100 μM) or thiourea (500 mM) was added
to the reaction mixture containing diethylene-triamine
pentaacetic acid (25 μM), FeSO4 (25 mM), H2O2 (100
μM), and DMPO (112.5 mM). These drugs and reagents
were solubilized in Milli Q water. The reaction mixture
was transferred to a flat quartz cuvette and placed in
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system (JEOL Ltd., Tokyo, Japan). The
.OH, which was
generated by Fenton’s reaction between Fe
2+ and H2O2,
was trapped by DMPO, and a stable adduct DMPO-OH
was measured exactly 1 min after the addition of
DMPO. The Mn
2+-derived split signal was used as the
internal standard. Typical instrumental stettings were as
follows: incident-microwave of 4 mV, modulation-ampli-
tude of 0.1 mT, time-constant of 0.10 s, and sweep rate
of 5 mT/min.
Hemiparkinsonian rats
Male Wistar rats (SLC, Shizuoka, Japan) weighing
approximately 250 g were used. Rats were acclimated
to and maintained at 23°C under a 12-hour light and
dark cycle (light on 08:00-20:00 hours). All animal
experiments were carried out in accordance with the
National Institutes of Health Guide for the Care and
Use of Laboratory Animals, and the protocols were
approved by the Committee for Animal Research at
Kyoto Pharmaceutical University. For stereotaxic
microinjection, rats were anesthetized (sodium pento-
barbital, 50 mg/kg, i.p.) and immobilized in a Kopf
stereotaxic frame. Subsequently, rats were simulta-
neously injected with 6-OHDA (32 nmol/4 μL) in the
presence or absence of comp-23 (4 nmol/4 μL), in a
final volume of 4 μL of physiological saline containing
0.02% ascorbic acid (as a 6-OHDA stabilizer) and 1%
dimethyl sulfoxide (DMSO, as a solvent for comp-23).
As a vehicle control, sterilized physiological saline
containing 0.02% ascorbic acid and 1% DMSO was
injected without 6-OHDA. The intranigral injection
coordinates 4.8 mm anterior-posterior, 1.8 mm left
lateral, and 7.8 mm ventral from the bregma were
taken from a rat brain atlas. Injection was performed
by a motor-driven 10-μl Hamilton syringe using a 26-
gauge needle. The infusion rate was 1 μL/min, and
the injection needle was kept in place for a further 5
min after injection. At the end of the experiments, all
rats were sacrificed for immunohistochemical
assessments.
Assay of rotational behavior
We used methamphetamine as a dopamine releaser
[38]. Drug-induced rotational asymmetry was
assessed in rotometer bowls as described previously
[20,23,39]. Briefly, the number of full body turn rota-
tions in the ipsilateral direction was counted after the
administration of methamphetamine (2.5 mg/kg, i.p.,
for 70 min).
Tissue preparation and immunohistochemistry
After assay of rotational behaviour, treated rats were
perfused through the aorta with 150 mL of 10 mM
PBS, followed by 300 mL of a cold fixative consisting
of 4% paraformaldehyde in 100 mM phosphate buffer
(PB) under deep anesthesia with pentobarbital (100
mg/kg, i.p.). After perfusion, the brain was quickly
r e m o v e da n dp o s t f i x e df o r2d a y sw i t hp a r a f o r m a l d e -
hyde in 100 mM PB and then transferred to 15%
sucrose solution in 100 mM PB containing 0.1%
sodium azide at 4°C. The brain was cut into 20-μm-
thick slices using a cryostat and collected in 100 mM
PBS containing 0.3% Triton X-100 (PBS-T). Brain
slices were incubated with a mouse anti-TH antibody
(1:10,000, dilution) for 3 days at 4°C. After several
washes, sections were incubated with biotinylated anti-
mouse IgG antibody (1:2,000), as appropriate, for 2
hours at room temperature. The sections were then
incubated with avidin peroxidase (1:4,000; ABC Elite
Kit; Vector Laboratories, Burlingame, CA, USA) for 1
hour at room temperature. All of the sections were
washed several times with PBS-T between each incuba-
tion, and labeling was then revealed by 3,3’-diamino-
benzidine (DAB) with nickel ammonium, which
yielded a dark blue colour [20,23].
Measurement of immunoreactive neurons and areas
The number of TH-immunopositive neurons in the sub-
stantia nigra and the optical density of TH-immunoreac-
tive areas in the striatum were measured by a
computerized image analysis system (WinRoof; Mitani,
Tokyo, Japan) with a CCD camera (ProgRes 3008, Carl
Zeiss, Jena, Germany) as described previously [20,23].
The number of TH-immunopositive neurons in the sub-
stantia nigra was counted bilaterally on six adjacent sec-
tions between 4.6 and 4.9 mm posterior from the
bregma. For each animal, neuronal survival in the sub-
stantia nigra was then expressed as the percentage of
TH-immunopositive neurons on the lesioned side, with
respect to the contralateral, intact side; this approach
was chosen to avoid methodological biases because of
interindividual differences and is widely used to assess
the extent of a 6-OHDA-induced lesion in the substan-
tia nigra [40-42].
For the analysis of striatal TH-immunoreactive inten-
sity, the striatum was divided into anatomo-functional
quadrants encompassing the dorsal (D), lateral (L), ven-
tral (V), and medial (M) regions [41,43] and the optical
density was measured within a fixed box (0.5 × 0.5 mm)
positioned approximately in the middle of these quad-
rantal parts. Immunoreactive intensity was expressed as
percentage of the intensity recorded from the same area
on the contralateral side [40,43,44]. Subsequently, the
average of relative intensities in each quadrant was esti-
mated from striatal slices (at 0.60 mm anterior from the
bregma) and then statistical values were evaluated from
treated rats.
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Male Wistar rats weighing 260-300 g were used. Focal
cerebral ischemia was induced by the intraluminal
introduction of a nylon thread as described previously
[ 2 1 ] .B r i e f l y ,a n i m a l sw e re anesthetized with 4%
halothane (Takeda Pharmaceutical, Osaka, Japan) and
maintained on 1.5% halothane using a facemask. After
a midline neck incision had been made, 20 mm of 4-0
nylon thread with its tip rounded by heating and
coated with silicone (Xantopren M; Heraeus Kulzer,
Hanau, Germany) was inserted into the left internal
carotid artery (ICA) as far as the proximal end using a
globular stopper. The origin of the middle cerebral
artery (MCA) was then occluded by a silicone-coated
embolus. Anesthesia was discontinued, and the devel-
opment of right hemiparesis with upper limb domi-
nance was used as the criterion for ischemic insult.
After 90 or 120 min of MCA occlusion (MCAO), the
embolus was withdrawn to allow reperfusion of the
ischemic region via the anterior and posterior commu-
nicating arteries. Body temperature was maintained at
37-37.5°C with a heating pad and lamp during surgery.
In the sham operation, a midline neck incision was
made to expose the arteries, but the nylon thread was
not inserted into the carotid artery.
Intrastriatal drug administration to ischemic rats
Ninety-min-MCAO-ischemic rats (SLC, Shizuoka) were
used. Under deep anesthesia (sodium pentobarbital, 50
mg/kg, i.p.), rats received a microinjection of comp-23
(4 nmol/4 μL) in the left striatum (coordinates: 1 mm
anterior, 4 mm left lateral, and 5 mm ventral from the
bregma). Sterilized physiological saline containing 1%
DMSO was used as the vehicle control in a final volume
of 4 μL. After 30 min, left MCAO for 90 min and reper-
fusion were performed.
Intraperitoneal drug administration to ischemic rats
One hundred twenty-min-MCAO-ischemic rats were
used. Animals were intraperitoneally administered with
comp-23 (0.1, 1 and 10 mg/kg), before 10 min and after
2 hours of the reperfusion from MCAO. Sterilized phy-
siological saline containing 1% DMSO was used as a
vehicle control.
Measurement of infarct volume in rat ischemic brain
At 24 hours after MCAO, brains were removed and cut
into 2-mm-thick coronal sections. These sections were
immersed in 2% solution of 2,3,5-triphenyltetrazolium
chloride (TTC; Wako Pure Chemical Industries, Osaka,
Japan) in saline at 37°C for 20 min and then fixed in 4%
paraformaldehyde in 100 mM phosphate buffer (PB) at
4°C, and infarct areas and volumes were quantified.
Rotenone-treated PD model mice and rota-rod test
Rotenone (Sigma, St. Louis, MO, USA) was adminis-
tered orally once daily at a dose of 30 mg/kg for 56
days, as described previously [30,31]. Rotenone was sus-
pended in 0.5% carboxymethyl cellulose sodium salt
(CMC, Nacalai Tesque, Kyoto, Japan) and administered
orally once daily at a volume of 5 mL/kg body weight.
0.5% CMC was administered orally as vehicle to control
mice.
Behaviour of each mouse was assessed by the rota-rod
test, as also described previously [30,31]. The rota-rod
treadmill (accelerating model 7750, Ugo Basile, Varese,
Italy) consists of a plastic rod, 6 cm in diameter and 36
cm long, with a non-slippery surface 20 cm above the
base (trip plate). This rod is divided into four equal sec-
tions by five discs (25 cm in diameter), which enables
four mice to walk on the rod at the same time. In the
present study, the accelerating rotor mode was used
(10-grade speeds from 2 to 20 r.p.m. for 5 min). The
performance time was recorded while mice were run-
ning on the rod.
Statistical evaluation
All data are presented as means ± standard error of the
mean (SEM). The significance of differences was deter-
mined by one-way analysis of variance (ANOVA).
Further statistical analysis for post hoc comparisons was
performed using the Bonferroni/Dunn tests (StatView;
Abacus Concepts, Berkeley, CA, USA). On the other
hand, the significance of difference in rotation numbers/
5 min and that of difference in areas of survival neurons
in 6-OHDA-injected rats and MCAO-ischemic rats were
determined by Student’s t-test for single comparisons.
Endurance performance (percentage of mice remaining
on the rota-rod) was calculated by the Kaplan-Meier
method. The statistical significance of differences was
analyzed by the log-rank (Mantel-Cox) test.
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